Metabolic impairment in heart failure: The myocardial and systemic perspective

Journal of the American College of Cardiology

Volumn 64, Issue 13, 2014, Pages 1388-1400

  Doehner, Wolfram ^a   Frenneaux, Michael ^b   Anker, Stefan D ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

cachexia; insulin resistance; metabolism; muscle; sarcopenia; stroke

Indexed keywords

ALLOPURINOL; CARDIOVASCULAR AGENT; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 2; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID; GLITAZONE DERIVATIVE; GROWTH HORMONE; INCRETIN; LIPOPROTEIN LIPASE; METFORMIN; PERHEXILINE; SAXAGLIPTIN; SZETO SCHILLER PEPTIDE; TRIMETAZIDINE; UNCLASSIFIED DRUG; STEROID;

BIOENERGY; BONE TISSUE; CACHEXIA; CARDIOVASCULAR EFFECT; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; ENERGY METABOLISM; ENERGY TRANSFER; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; HEART FAILURE; HEART MUSCLE METABOLISM; HORMONAL REGULATION; HORMONE RESISTANCE; HUMAN; HYPERURICEMIA; INSULIN RESISTANCE; IRON DEFICIENCY ANEMIA; NONHUMAN; PATHOPHYSIOLOGY; RESPIRATORY CHAIN; REVIEW; SKELETAL MUSCLE; STEROID METABOLISM; WASTING SYNDROME; CEREBROVASCULAR ACCIDENT; DISEASE COURSE; HEART MUSCLE; METABOLISM; MUSCLE; PATHOLOGY; PROGNOSIS; SARCOPENIA;

CACHEXIA; INSULIN RESISTANCE; METABOLISM; MUSCLE; SARCOPENIA; STROKE;

CACHEXIA; DISEASE PROGRESSION; ENERGY METABOLISM; GROWTH HORMONE; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MUSCLE, SKELETAL; MYOCARDIUM; PROGNOSIS; SARCOPENIA; STEROIDS; STROKE;

EID: 84908294192     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.04.083     Document Type: Review

References (124)

1. J. Fang, G.A. Mensah, and J.B. Croft Heart failure-related hospitalization in the U.S., 1979 to 2004 J Am Coll Cardiol 52 2008 428 434
2. M.F. Piepoli, A. Kaczmarek, and D.P. Francis Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure Circulation 114 2006 126 134
3. P. Attanasio, S.D. Anker, and W. Doehner Hormonal consequences and prognosis of chronic heart failure Curr Opin Endocrinol Diabetes Obes 18 2011 224 230
4. S. von Haehling, W. Doehner, and S.D. Anker Nutrition, metabolism and the complex pathophysiology of cachexia in chronic heart failure Cardiovasc Res 73 2007 298 309
5. S.D. Anker, T.P. Chua, and P. Ponikowski Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia Circulation 96 1997 526 534
6. E.A. Jankowska, B. Biel, and J. Majda Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival Circulation 114 2006 1829 1837
7. S.E. Malmberg, and C.M. Adams Insulin signaling and the general amino acid control response. Two distinct pathways to amino acid synthesis and uptake J Biol Chem 283 2008 19229 19234
8. M.J. Toth, M.M. LeWinter, and P.A. Ades Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation Clin Sci (Lond) 119 2010 467 476
9. X. Wang, Z. Hu, and J. Hu Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling Endocrinology 147 2006 4160 4168
10. J.W. Swan, S.D. Anker, and C. Walton Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure J Am Coll Cardiol 30 1997 527 532
11. W. Doehner, M. Rauchhaus, and P. Ponikowski Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure J Am Coll Cardiol 46 2005 1019 1026
12. A. Tenenbaum, and E.Z. Fisman Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies Am J Cardiovasc Drugs 4 2004 269 280
13. W. Doehner, M. Rauchhaus, and I.F. Godsland Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha Int J Cardiol 83 2002 73 81
14. W. Doehner, C.D. Pflaum, and M. Rauchhaus Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia Eur J Endocrinol 145 2001 727 735
15. S.D. Anker, M. Volterrani, and C.D. Pflaum Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone J Am Coll Cardiol 38 2001 443 452
16. K.J. Osterziel, O. Strohm, and J. Schuler Randomised, double blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy Lancet 351 1998 1233 1237
17. E.A. Jankowska, G. Filippatos, and B. Ponikowska Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure J Card Fail 15 2009 442 450
18. N. Nagaya, M. Uematsu, and M. Kojima Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors Circulation 104 2001 2034 2038
19. D.S. Frankel, R.S. Vasan, and R.B. D'Agostino Sr. Resistin, adiponectin, and risk of heart failure the Framingham offspring study J Am Coll Cardiol 53 2009 754 762
20. T. Szabó, N. Scherbakov, and A. Sandek Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis Nutr Metab Cardiovasc Dis 24 2014 50 56
21. A.L. Birkenfeld, M. Boschmann, and C. Moro Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans J Clin Endocrinol Metab 90 2005 3622 3628
22. A. Sandek, J. Bauditz, and A. Swidsinski Altered intestinal function in patients with chronic heart failure J Am Coll Cardiol 50 2007 1561 1569
23. R. Ventura-Clapier Exercise training, energy metabolism, and heart failure Appl Physiol Nutr Metab 34 2009 336 339
24. J.A. Madrazo, and D.P. Kelly The PPAR trio: regulators of myocardial energy metabolism in health and disease J Mol Cell Cardiol 44 2008 968 975
25. P.C. Schulze, S. Gielen, and V. Adams Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure Basic Res Cardiol 98 2003 267 274
26. L.D. Libera, and G. Vescovo Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation? Curr Opin Clin Nutr Metab Care 7 2004 435 441
27. A. Breitbart, M. Auger-Messier, and J.D. Molkentin Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting Am J Physiol Heart Circ Physiol 300 2011 H1973 H1982
28. S. Girgenrath, K. Song, and L.A. Whittemore Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle Muscle Nerve 31 2005 34 40
29. M.R. Hoenig Hypothesis: myostatin is a mediator of cardiac cachexia Int J Cardiol 124 2008 131 133
30. D.M. Mancini, G. Walter, and N. Reichek Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure Circulation 85 1992 1364 1373
31. D. Harrington, S.D. Anker, and T.P. Chua Skeletal muscle function and its relation to exercise tolerance in chronic heart failure J Am Coll Cardiol 30 1997 1758 1764
32. A.H. Berg, and P.E. Scherer Adipose tissue, inflammation, and cardiovascular disease Circ Res 96 2005 939 949
33. M. Rydén, and P. Arner Fat loss in cachexia - is there a role for adipocyte lipolysis? Clin Nutr 26 2007 1 6
34. M. Rydén, E. Arvidsson, and L. Blomqvist Targets for TNF-alpha-induced lipolysis in human adipocytes Biochem Biophys Res Commun 318 2004 168 175
35. C. Sengenès, M. Berlan, and I. De Glisezinski Natriuretic peptides: a new lipolytic pathway in human adipocytes FASEB J 14 2000 1345 1351
36. M. Lafontan, C. Moro, and M. Berlan Control of lipolysis by natriuretic peptides and cyclic GMP Trends Endocrinol Metab 19 2008 130 137
37. T. Szabó, E. Postrach, and A. Mähler Increased catabolic activity in adipose tissue of patients with chronic heart failure Eur J Heart Fail 15 2013 1131 1137
38. Y.H. Yu, and H.N. Ginsberg Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue Circ Res 96 2005 1042 1052
39. C. Kistorp, J. Faber, and S. Galatius Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure Circulation 112 2005 1756 1762
40. M.B. McEntegart, B. Awede, and M.C. Petrie Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide Eur Heart J 28 2007 829 835
41. E. Shane, D. Mancini, and K. Aaronson Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure Am J Med 103 1997 197 207
42. S. Abou-Raya, and A. Abou-Raya Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden Arch Gerontol Geriatr 49 2009 250 254
43. S.D. Anker, A.L. Clark, and M.M. Teixeira Loss of bone mineral in patients with cachexia due to chronic heart failure Am J Cardiol 83 1999 612 615
44. E.A. Jankowska, J. Jakubaszko, and A. Cwynar Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants Eur J Heart Fail 11 2009 28 38
45. A. Zittermann, S.S. Schleithoff, and R. Koerfer Markers of bone metabolism in congestive heart failure Clin Chim Acta 366 2006 27 36
46. B. Bozic, G. Loncar, and N. Prodanovic Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure J Card Fail 16 2010 301 307
47. W. Doehner, and S.D. Anker Cardiac cachexia in early literature: a review of research prior to Medline Int J Cardiol 85 2002 7 14
48. S.D. Anker, P. Ponikowski, and S. Varney Wasting as independent risk factor for mortality in chronic heart failure Lancet 349 1997 1050 1053
49. S. von Haehling, and S.D. Anker Cachexia as a major underestimated and unmet medical need: facts and numbers J Cachexia Sarcopenia Muscle 1 2010 1 5
50. M. Muscaritoli, S.D. Anker, and J. Argilés Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics." Clin Nutr 29 2010 154 159
51. S.D. Anker, A. Negassa, and A.J. Coats Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study Lancet 361 2003 1077 1083
52. M. Lainscak, S. von Haehling, and W. Doehner The obesity paradox in chronic disease: facts and numbers J Cachexia Sarcopenia Muscle 3 2012 1 4
53. W.J. Evans, J.E. Morley, and J. Argilés Cachexia: a new definition Clin Nutr 27 2008 793 799
54. J.N. Nanas, C. Matsouka, and D. Karageorgopoulos Etiology of anemia in patients with advanced heart failure J Am Coll Cardiol 48 2006 2485 2489
55. I. Theurl, E. Aigner, and M. Theurl Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications Blood 113 2009 5277 5286
56. M.W. Hentze, M.U. Muckenthaler, and B. Galy Two to tango: regulation of Mammalian iron metabolism Cell 142 2010 24 38
57. E. Nemeth, S. Rivera, and V. Gabayan IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J Clin Invest 113 2004 1271 1276
58. H. Huang, M. Constante, and A. Layoun Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli Blood 113 2009 3593 3599
59. J.A. Ezekowitz, F.A. McAlister, and P.W. Armstrong Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure Circulation 107 2003 223 225
60. G. Weiss, and L.T. Goodnough Anemia of chronic disease N Engl J Med 352 2005 1011 1023
61. S.D. Anker, J. Comin Colet, G. Filippatos for the FAIR-HF Trial Investigators Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2009 2436 2448
62. E.A. Jankowska, P. Rozentryt, and A. Witkowska Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure J Card Fail 17 2011 899 906
63. R. Lill, and U. Muhlenhoff Iron-sulfur protein biogenesis in eukaryotes: components and mechanisms Annu Rev Cell Dev Biol 22 2006 457 486
64. M.L. Huang, D.J. Lane, and D.R. Richardson Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease Antioxid Redox Signal 15 2011 3003 3019
65. W. Doehner, M. Rauchhaus, and V.G. Florea Uric acid in cachectic and non-cachectic patients with chronic heart failure: relationship to leg vascular resistance Am Heart J 141 2001 792 799
66. S.D. Anker, W. Doehner, and M. Rauchhaus Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging Circulation 107 2003 1991 1997
67. W.C. Levy, D. Mozaffarian, and D.T. Linker The Seattle Heart Failure Model: prediction of survival in heart failure Circulation 113 2006 1424 1433
68. F. Leyva, T.P. Chua, and S.D. Anker Uric acid in chronic heart failure: a measure of the anaerobic threshold Metabolism 47 1998 1156 1159
69. F. Leyva, C.S. Wingrove, and I.F. Godsland The glycolytic pathway to coronary heart disease: a hypothesis Metabolism 47 1998 657 662
70. M. Ashraf, and Z.Q. Samra Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study J Submicrosc Cytol Pathol 25 1993 193 201
71. W. Doehner, and U. Landmesser Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options Semin Nephrol 31 2011 433 440
72. W. Doehner, S. von Haehling, and S.D. Anker Uric acid in CHF: marker or player in a metabolic disease? Int J Cardiol 115 2007 156 158
73. K. Ogino, M. Kato, and Y. Furuse Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double blind placebo-controlled cross-over preliminary study Circ Heart Fail 3 2010 73 81
74. W.S. Waring, J.A. McKnight, and D.J. Webb Lowering serum urate does not improve endothelial function in patients with type 2 diabetes Diabetologia 50 2007 2572 2579
75. C. Korvald, O.P. Elvenes, and T. Myrmel Myocardial substrate metabolism influences left ventricular energetics in vivo Am J Physiol Heart Circ Physiol 278 2000 H1345 H1351
76. R.M. Bersin, C. Wolfe, and M. Kwasman Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate J Am Coll Cardiol 23 1994 1617 1624
77. H. Tuunanen, E. Engblom, and A. Naum Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure Circulation 114 2006 2130 2137
78. M. Halbirk, H. Nørrelund, and N. Møller Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure Am J Physiol Heart Circ Physiol 298 2010 H1096 H1102
79. W.C. Stanley, E.E. Morgan, and H. Huang Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia Am J Physiol Heart Circ Physiol 289 2005 H2304 H2309
80. J.A. Kennedy, S.A. Unger, and J.D. Horowitz Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone Biochem Pharmacol 52 1996 273 280
81. V. Lionetti, A. Linke, and M.P. Chandler Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure Cardiovasc Res 66 2005 454 461
82. M. Schwarzer, G. Faerber, and T. Rueckauer The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo Basic Res Cardiol 104 2009 547 557
83. S. Schmidt-Schweda, and C. Holubarsch First clinical trial with etomoxir in patients with chronic congestive heart failure Clin Sci (Lond) 99 2000 27 35
84. C.J. Holubarsch, M. Rohrbach, and M. Karrasch A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose) study Clin Sci (Lond) 113 2007 205 212
85. J.D. Horowitz, S.T. Sia, and P.S. Macdonald Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics Int J Cardiol 13 1986 219 229
86. L. Lee, R. Campbell, and M. Scheuermann-Freestone Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment Circulation 112 2005 3280 3288
87. K. Abozguia, P. Elliott, and W. McKenna Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy Circulation 122 2010 1562 1569
88. J.A. Kennedy, K. Beck-Oldach, and K. McFadden-Lewis Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation Eur J Pharmacol 531 2006 13 19
89. D.T. Ngo, N.E. Drury, and D. Pagano How does perhexiline modulate myocardial energetics and ameliorate redox stress (abstr)? Circulation 124 2011 A14461
90. A.D. Balgi, B.D. Fonseca, and E. Donohue Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling PLoS One 4 2009 e7124
91. A.R. Panchal, W.C. Stanley, and J. Kerner Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure J Card Fail 4 1998 121 126
92. T.R. Wallhaus, M. Taylor, and T.R. DeGrado Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure Circulation 103 2001 2441 2446
93. Y. Kusaka, T. Tanaka, and F. Okamoto Effect of sulfo-N-succinimidyl palmitate on the rat heart: myocardial long-chain fatty acid uptake and cardiac hypertrophy J Mol Cell Cardiol 27 1995 1605 1612
94. P.F. Kantor, A. Lucien, and R. Kozak The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase Circ Res 86 2000 580 588
95. H. Tuunanen, E. Engblom, and A. Naum Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy Circulation 118 2008 1250 1258
96. L. Zhang, Y. Lu, and H. Jiang Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis J Am Coll Cardiol 59 2012 913 922
97. G. Fragasso, G. Perseghin, and F. De Cobelli Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur Heart J 27 2006 942 948
98. L. Maier, R. Wachter, and F. Edelmann Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: results from the RALI-DHF study (abstr) J Am Coll Cardiol 59 2012 E865
99. P.D. Home, S.J. Pocock, H. Beck-Nielsen for the RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised open-label trial Lancet 373 2009 2125 2135
100. W. Doehner, E. Erdmann, and R. Cairns Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population Int J Cardiol 162 2012 20 26
101. F.A. Masoudi, S.E. Inzucchi, and Y. Wang Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study Circulation 111 2005 583 590
102. A.K. Wong, R. Symon, and M.A. Alzadjali The effect of metformin on insulin resistance and exercise parameters in patients with heart failure Eur J Heart Fail 14 2012 1303 1310
103. R. Rachmani, I. Slavachevski, and Z. Levi Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications Eur J Intern Med 13 2002 428
104. S.P. Romero, J.L. Andrey, and A. Garcia-Egido Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community Int J Cardiol 166 2013 404 412
105. B.M. Scirica, D.L. Bhatt, E. Braunwald for the SAVOR-TIMI Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
106. J. Nagendran, G.Y. Oudit, and J.A. Bakal Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes? Diabetes Obes Metab 15 2013 1022 1028
107. S.E. Schriner, N.J. Linford, and G.M. Martin Extension of murine life span by overexpression of catalase targeted to mitochondria Science 308 2005 1909 1911
108. D.F. Dai, L.F. Santana, and M. Vermulst Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging Circulation 119 2009 2789 2797
109. K. Zhao, G.M. Zhao, and D. Wu Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury J Biol Chem 279 2004 34682 34690
110. D.F. Dai, T. Chen, and H. Szeto Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy J Am Coll Cardiol 58 2011 73 82
111. M.P. Siegel, S.E. Kruse, and J.M. Percival Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice Aging Cell 12 2013 763 771
112. D.F. Dai, E.J. Hsieh, and T. Chen Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides Circ Heart Fail 6 2013 1067 1076
113. K. Folkers, P. Langsjoen, and P.H. Langsjoen Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant Biochem Biophys Res Commun 182 1992 247 253
114. S. Sander, C.I. Coleman, and A.A. Patel The impact of coenzyme Q10 on systolic function in patients with chronic heart failure J Card Fail 12 2006 464 472
115. G.A. Hirsch, P.A. Bottomley, and G. Gerstenblith Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts J Am Coll Cardiol 59 2012 802 808
116. W. Doehner, and S.D. Anker Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart 91 2005 707 709
117. L. Wei, T. Fahey, and A.D. Struthers Association between allopurinol and mortality in heart failure patients: a long-term follow-up study Int J Clin Pract 63 2009 1327 1333
118. J.M. Hare, B. Mangal, J. Brown for the OPT-CHF Investigators Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study J Am Coll Cardiol 51 2008 2301 2309
119. S. Ferraro, C. Codella, and F. Palumbo Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo Clin Cardiol 19 1996 699 703
120. S. Fumagalli, F. Fattirolli, and L. Guarducci Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study Clin Cardiol 34 2011 211 217
121. Y. Masumura, A. Kobayashi, and N. Yamazaki Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure Jpn Circ J 54 1990 1471 1476
122. J.J. DiNicolantonio, C.J. Lavie, and H. Fares L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis Mayo Clin Proc 88 2013 544 551
123. C.J. Malkin, P.J. Pugh, and J.N. West Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial Eur Heart J 27 2006 57 64
124. J.J. McMurray, S. Adamopoulos, and S.D. Anker ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur J Heart Fail 14 2012 803 869